AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Anti-cancer and Anti-obesity Cyclic Peptide Agents

Summary
This invention relates to a compound for anticancer and anti-obesity, and particularly, but not exclusively, a compound based on cyclic peptide agents for anticancer and anti-obesity.
Technology Benefits
Reducing the side effects
Technology Application
For use in anticancer or anti-obesity.
Detailed Technology Description
The present invention is based, at least in part, on the discovery that cyclopeptide compounds such as compounds isolated from the dry stem barks of the decayed woods of the plant Maytenus variabilis (Loes.) C. Y. Cheng (Celastraceae) are effective in the treatment of cancer and obesity diseases. Compounds of the invention may exist in different forms, such as free acids, free bases, enantiomers, esters and other prodrugs, salts and tautomers, for example, and the disclosure includes all variant forms of these compounds.
Supplementary Information
Inventor: Zhang, Hongjie
Priority Number: US20140107018A1
IPC Current: C07K000764
US Class: 5140048 | 5140193 | 530321 | 562506
Assignee Applicant: Hong Kong Baptist University
Title: ANTICANCER AND ANTI-OBESITY CYCLIC PEPTIDE AGENTS
Usefulness: ANTICANCER AND ANTI-OBESITY CYCLIC PEPTIDE AGENTS
Summary: (I) are useful alone or in combination with clinically used anticancer or anti-obesity agent for treating, preventing or delaying the of progression of cancer or obesity in a human (all claimed).
Novelty: New cyclopeptide compounds used anticancer or anti-obesity agent for treating, preventing or delaying the of progression of cancer or obesity
Industry
Disease Diagnostic/Treatment
Sub Category
Cancer/Tumor
Application Date
2013.03.14
Application No.
US 13/804,276
Others
Filed
ID No.
A61/ZH/Obes/US01
Country/Region
Hong Kong

For more information, please click Here
Mobile Device